Trials / Completed
CompletedNCT04695431
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 317 (actual)
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
Conditions
- Advanced Systemic Mastocytosis
- Aggressive Systemic Mastocytosis
- Systemic Mastocytosis With an Associated Hematological Neoplasm
- Mast Cell Leukemia
Timeline
- Start date
- 2020-12-02
- Primary completion
- 2021-10-04
- Completion
- 2021-10-04
- First posted
- 2021-01-05
- Last updated
- 2022-01-10
Locations
6 sites across 5 countries: United States, Austria, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04695431. Inclusion in this directory is not an endorsement.